The Most-Favored-Nation Pricing Agreement: Implications for Pfizer and U.S. Consumers
On September 30, 2025, current President, Donald Trump and pharmaceutical and biotechnology giant, Pfizer Inc. announced a historical agreement to implement Most-Favored-Nation (MFN) pricing for many of Pfizer’s prescription drugs.
Read More